StreetInsider.com News Articles

Form 6-K PSYENCE BIOMEDICAL LTD. For: Aug 06

Thu, 06 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26883333.html

Form 6-K PSYENCE BIOMEDICAL LTD. For: Aug 06

Thu, 06 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26883333.html

Form 6-K PSYENCE BIOMEDICAL LTD. For: Aug 06

Thu, 06 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26883333.html

Form 6-K PSYENCE BIOMEDICAL LTD. For: Aug 06

Thu, 06 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26883333.html

Form 20-F PSYENCE BIOMEDICAL LTD. For: Mar 31

Mon, 22 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260622/26672899.html

Form 20-F PSYENCE BIOMEDICAL LTD. For: Mar 31

Mon, 22 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260622/26672899.html

Form 20-F PSYENCE BIOMEDICAL LTD. For: Mar 31

Mon, 22 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260622/26672899.html

Form 20-F PSYENCE BIOMEDICAL LTD. For: Mar 31

Mon, 22 Jun 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260622/26672899.html

Form SCHEDULE 13G/A PSYENCE BIOMEDICAL LTD. Filed by: Weiner Jeffrey David

Wed, 10 Jun 2026 15:09:00 -0400

si-local-file:///var/storage/secattach/20260610/26629502.html

Form SCHEDULE 13G/A PSYENCE BIOMEDICAL LTD. Filed by: Weiner Jeffrey David

Wed, 10 Jun 2026 15:09:00 -0400

si-local-file:///var/storage/secattach/20260610/26629502.html

Form SCHEDULE 13G/A PSYENCE BIOMEDICAL LTD. Filed by: Weiner Jeffrey David

Wed, 10 Jun 2026 15:09:00 -0400

si-local-file:///var/storage/secattach/20260610/26629502.html

Form SCHEDULE 13G/A PSYENCE BIOMEDICAL LTD. Filed by: Weiner Jeffrey David

Wed, 10 Jun 2026 15:09:00 -0400

si-local-file:///var/storage/secattach/20260610/26629502.html

Form 6-K PSYENCE BIOMEDICAL LTD. For: Jun 05

Fri, 05 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260605/26611278.html

Form 6-K PSYENCE BIOMEDICAL LTD. For: Jun 05

Fri, 05 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260605/26611278.html

Form 6-K PSYENCE BIOMEDICAL LTD. For: Jun 05

Fri, 05 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260605/26611278.html

Form 6-K PSYENCE BIOMEDICAL LTD. For: Jun 05

Fri, 05 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260605/26611278.html

Form SCHEDULE 13D PSYENCE BIOMEDICAL LTD. Filed by: Psyence Labs Ltd

Wed, 03 Jun 2026 09:28:00 -0400

si-local-file:///var/storage/secattach/20260603/26596684.html

Form SCHEDULE 13D PSYENCE BIOMEDICAL LTD. Filed by: Psyence Labs Ltd

Wed, 03 Jun 2026 09:28:00 -0400

si-local-file:///var/storage/secattach/20260603/26596684.html

Form SCHEDULE 13D PSYENCE BIOMEDICAL LTD. Filed by: Psyence Labs Ltd

Wed, 03 Jun 2026 09:28:00 -0400

si-local-file:///var/storage/secattach/20260603/26596684.html

Form SCHEDULE 13D PSYENCE BIOMEDICAL LTD. Filed by: Psyence Labs Ltd

Wed, 03 Jun 2026 09:28:00 -0400

si-local-file:///var/storage/secattach/20260603/26596684.html

Psyence BioMed executives to visit US for ibogaine research meetings

Fri, 15 May 2026 09:15:54 -0400

Psyence BioMed Ltd. (NASDAQ: PBM) announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in psychedelic medicine research and policy initiatives.

The company said the visit follows recent U.S. policy developments supporting increased research collaboration and clinical investigation involving psychedelic compounds, including ibogaine. Chief Executive Officer Jody Aufrichtig submitted a formal letter to President Donald J. Trump and U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. regarding the Administration's research initiatives involving psychedelic compounds.

The purpose of the engagement

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Fri, 15 May 2026 09:15:00 -0400

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.

The visit follows recent U.S. policy developments supporting increased research collaboration, regulatory review pathways, and clinical investigation involving psychedelic compounds,

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Fri, 15 May 2026 09:15:00 -0400

The visit follows recent U.S. policy developments supporting increased research collaboration, regulatory review pathways, and clinical investigation involving psychedelic compounds,

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Fri, 15 May 2026 09:15:00 -0400

The visit follows recent U.S. policy developments supporting increased research collaboration, regulatory review pathways, and clinical investigation involving psychedelic compounds,

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Fri, 15 May 2026 09:15:00 -0400

The visit follows recent U.S. policy developments supporting increased research collaboration, regulatory review pathways, and clinical investigation involving psychedelic compounds,